HESTERBIO Hester Bios Q1 FY26 results (Apr–Jun 2025) and concall
Hester Biosciences reported a mixed Q1 FY26 with standalone performance impacted by delayed institutional orders and a 14% revenue degrowth to INR63 crores, alongside a 7% PAT decline. However, consolidated PAT grew over 100% driven by a strong turnaround in Hester Africa, which posted a INR5 crore profit on INR17 crore revenue. The company remains optimistic about returning to growth in the coming quarters with normalizing institutional demand and new product momentum.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 |
|---|---|---|---|---|
| Revenue | 74 | 63 | 77 | 63 |
| EBITDA | 15 | 9 | 14 | 12 |
| Net profit | 9 | 4 | 10 | 8 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
